Get the Stockscreener App
3.38
0.60%
0.02
Soligenix Inc stock is traded at $3.38, with a volume of 591.02K.
It is up +0.60% in the last 24 hours and up +139.72% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$3.36
Open:
$3.25
24h Volume:
591.02K
Relative Volume:
0.06
Market Cap:
$11.03M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.4471
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
+21.58%
1M Performance:
+139.72%
6M Performance:
+39.09%
1Y Performance:
-20.28%
1-Day Range:
$3.21
$3.44
1-Week Range:
$3.21
$6.2299
52-Week Range:
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
3.38 | 16.19M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Are Bears Losing Grip on Soligenix Inc.2025 Top Gainers & Fast Entry Momentum Trade Alerts - newsyoung.net
NovaBay Names New CEO, Rocket Soars As FDA Lifts Clinical Hold, Celldex Plunges, Soligenix On Watch - RTTNews
Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky - Yahoo Finance
SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease - Yahoo Finance
Soligenix shares rise 9.46% premarket after receiving Nasdaq notice for non-compliance with equity requirement. - AInvest
Top Penny Stocks to Watch Now: Soligenix, Catheter Precision, and Wellgistics Health - AInvest
Promising Defense Stocks To Add to Your WatchlistAugust 18th - MarketBeat
Soligenix Plunges 27%—What's Behind the Sudden Sell-Off Amid Orphan Drug Designation? - AInvest
Soligenix (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease - The Globe and Mail
Why SNGX Gains 8% Amid Positive Trends? - StocksToTrade
Soligenix Plunges 17.74% After FDA Orphan Drug Designation - AInvest
Soligenix shares fall 18.55% premarket after receiving Nasdaq notice for non-compliance with equity requirement. - AInvest
Soligenix's 78.42% Surge on FDA Orphan Drug Designation Drives $890M Trading Volume Ranks 87th in Market Activity - AInvest
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
FDA Grants Orphan Drug Designation to Soligenix's Dusquetide for Behçet’s Disease Treatment - citybuzz -
Soligenix Skyrockets 87%—Is This the Start of a Biotech Revolution? - AInvest
Top Midday Gainers - MarketScreener
Why Is Soligenix Stock Soaring On Monday? - Benzinga
Soligenix (SNGX.O) Makes Wild Intraday Move—What’s Driving It? - AInvest
Soligenix Shares Surge After FDA Grants Orphan Drug Status - MSN
Regression Model Predicts Rangebound Movement in Soligenix Inc.2025 Big Picture & Daily Technical Forecast Reports - beatles.ru
Soligenix stock soars after FDA grants orphan drug designation By Investing.com - Investing.com Canada
Soligenix (SNGX) up more than 300% since Jul 29 - AInvest
Soligenix stock soars after FDA grants orphan drug designation - Investing.com
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results - The Malaysian Reserve
Soligenix (SNGX) Stock Surges on FDA Orphan Drug Designation for Rare Disease Treatment – A Big Win for This Biotech Underdog - RagingBull
Soligenix Inc.: An Unexpected Surge? - StocksToTrade
Soligenix Soars 90% on FDA Orphan Drug Designation – What’s Next for SNGX? - AInvest
Soligenix Gains FDA Orphan Drug Designation for Dusquetide - TipRanks
FDA grants soligenix orphan drug designation for behçet’s disease - Investing.com
Why Soligenix Is Rising In Pre-market? - Nasdaq
2025-08-18 | FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results | NDAQ:SNGX | Press Release - Stockhouse
Drawdown in Soligenix Inc. May Be Nearing EndStock Surge & AI Forecasted Entry and Exit Points - beatles.ru
Soligenix Faces Nasdaq Non-Compliance Notice - MSN
New Study Challenges Traditional Psoriasis Severity Classification - citybuzz -
Soligenix's Nasdaq Non-Compliance: A High-Stakes Balancing Act for Long-Term Investors - AInvest
Soligenix Receives Nasdaq Notice for Non-Compliance with Equity Requirement - AInvest
Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns - citybuzz -
Soligenix receives Nasdaq notice for non-compliance with equity listing rule - Investing.com
Soligenix shares fall 5.78% premarket after announcing recent accomplishments and financial results. - AInvest
What makes Soligenix Inc. stock price move sharplyEarnings Beat & Smart Investment Allocation Insights - 선데이타임즈
Soligenix's Surprising Earnings Beat Amid Deepening Losses and High Volatility: A Biotech Inflection Point? - AInvest
Soligenix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Soligenix Reports Q2 2025 Results, Confident in Late-Stage Rare Disease Pipeline - AInvest
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results - Barchart.com
Soligenix’s Phase 3 Study on HyBryte for CTCL: Key Insights for Investors - MSN
Soligenix Inc. Stock Recovery Path — Analyst BreakdownJuly 2025 Rallies & Consistent Income Trade Recommendations - 선데이타임즈
Is Soligenix Inc. a stock for growth or value investorsFast Explosive Return Stocks - newsyoung.net
Alliance Global Partners Raises Soligenix Price Target Amid Clinical Advancements - citybuzz -
Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix (NASDAQ: SNGX) Advances Proprietary Clinical Programs - Barchart.com
How do insiders feel about Soligenix Inc.Free Investment Newsletter - classian.co.kr
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):